Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up
2016
Background
Imatinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). Cutaneous adverse reactions of imatinib therapy have been reported in 7%-88.9% patients.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
11
Citations
NaN
KQI